Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial
Objective: To investigate synaptic loss in Parkinson's Disease depression (PDd) using PET and [11C]UCB-J (a marker for synaptic density) and present the initial blinded findings…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease
Objective: The aim was to carry out a long-term follow-up of a cohort of patients in late stage Parkinson’s disease (PD) with focus on mortality…Relationships of blood Vitamin B12 and Homocysteine with Parkinson’s Disease Progression in 3 Contemporary Clinical Trials
Objective: To measure blood levels of vitamin B12 and homocysteine (tHcy) in contemporary clinical trial participants and to determine whether these analytes were associated with…Possible Sarcopenia and its Association with Physical Activity among Parkinson’s disease Patients
Objective: This study aimed to screen the prevalence of possible sarcopenia and its association with physical activity level in a sample of PD patients. Background:…Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein
Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…Nocturnal Hypertension in Parkinson’s Disease. The Flip Side of a Tainted Coin
Objective: To describe prevalence and severity of nocturnal hypertension and dipping in a cohort of patients with Parkinson’s disease undergoing 24hr blood pressure (BP) monitoring.…Stigmatizing Attitudes Towards People With PD Using The Parkinson’s Disease Social Stigma Perception Scale (PDSP): A Nationwide Study
Objective: This study aimed to: 1) identify factors associated with stigma towards people living with Parkinson's Disease (PwP), and 2) analyze sociodemographic-based variations in the…Motor Impact of Fasting in Parkinson’s Disease Patients: An overview
Objective: To provide a literature overview of fasting impact on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…
- « Previous Page
- 1
- …
- 136
- 137
- 138
- 139
- 140
- …
- 1554
- Next Page »